



Clinical Data's Cogenics Division Provides Exclusive Global Genotyping Solutions for Astellas

NEWTON, Mass., Nov 24, 2008 (BUSINESS WIRE) --

Clinical Data, Inc. (NASDAQ: CLDA) announced today that its Cogenics division, the global leader in outsourced genomics services, has become the exclusive global provider of genotyping solutions for Astellas Pharma Inc. Cogenics' offerings will include biorepository and extraction services in combination with whole genome association and targeted genotyping for Astellas' clinical studies in the United States, Europe and Asia.

"We are pleased to partner with Astellas, one of the world's top pharmaceutical companies, to be their exclusive provider in offering our full spectrum of genotyping services," said Michael Lutz, Global Manager of Cogenics. "As life sciences' research and pharmaceutical development truly becomes a global endeavor, we are well positioned to deliver comprehensive genotyping solutions to our customers worldwide."

Cogenics provides next generation sequencing, gene expression, clinical and non-clinical genotyping, biomanufacturing support, nucleic acid extraction and biobanking for both research and regulated environments. Cogenics has facilities in North Carolina, Texas, United Kingdom, France and Germany.

For more information about Cogenics and its genomic services offerings, please call 1-877-226-4364 (U.S.) or +49 (0) 8158 - 99 85-0 (E.U.) or email sales@cogenics.com.

About Cogenics

Cogenics, a division of Clinical Data, has established itself as a leading provider of value-based genomics solutions for both the Healthcare and Life Sciences industries. These solutions span the areas of current and next generation sequencing, gene expression, clinical and non-clinical genotyping, biomanufacturing support, nucleic acid extraction and biobanking for both research and regulated environments. Its customers include some of the world's most respected pharmaceutical and biotechnology companies, agencies of the US National Institutes of Health, leading government and academic researchers in the international life science community, and major agricultural companies and agencies. For more information, please visit www.cogenics.com.

About Clinical Data, Inc.

Clinical Data is a global biotechnology company unlocking the potential of molecular discovery, From Targeted Science to Better Healthcare^(R). The Company's PGxHealth division is utilizing its biomarker intellectual property to develop and commercialize a broad pipeline of targeted therapeutics as well as pharmacogenetic tests that help predict drug safety and efficacy, thereby reducing health care costs. Its Cogenics division provides genomics services to both research and regulated environments. Through these divisions, Clinical Data is leveraging advances in molecular discovery to provide tangible benefits for patients, doctors, scientists and health plans worldwide. Please visit the Company's website at www.clda.com for more information.

SAFE HARBOR STATEMENT UNDER THE PRIVATE SECURITIES LITIGATION REFORM ACT OF 1995

This press release contains certain forward-looking information and statements that are intended to be covered by the safe harbor for forward looking statements provided by the Private Securities Litigation Reform Act of 1995. Forward-looking statements are statements that are not historical facts. Words such as "expect(s)", "feel(s)", "believe(s)", "will", "may", "anticipate(s)" and similar expressions are intended to identify forward-looking statements. These statements include, but are not limited to, our ability to successfully introduce our new products and services; our ability to expand our long-term business opportunities; financial projections and estimates and their underlying assumptions; and statements regarding future performance. All of such information and statements are subject to certain risks and uncertainties, the effects of which are difficult to predict and generally beyond the control of the Company, that could cause actual results to differ materially from those expressed in, or implied or projected by, the forward-looking information and statements. These risks and uncertainties include, but are not limited to, whether our Cogenics services will gain wide acceptance in the market; the strength of our intellectual property rights; competition from pharmaceutical, biotechnology and diagnostics companies; the development of and our ability to take advantage of the market for Cogenics' services; changes in government regulations, and changing relationships with customers, payers, suppliers and strategic partners; whether Clinical Data will be able to develop or acquire

additional products and attract new business and strategic partners; and those risks identified and discussed by Clinical Data in its filings with the U.S. Securities and Exchange Commission. Readers are cautioned not to place undue reliance on these forward looking statements that speak only as of the date hereof. Clinical Data does not undertake any obligation to republish revised forward-looking statements to reflect events or circumstances after the date hereof or to reflect the occurrence of unanticipated events. Readers are also urged to carefully review and consider the various disclosures in Clinical Data's SEC periodic and interim reports, including but not limited to its Annual Report on Form 10-K for the fiscal year ended March 31, 2008, Quarterly Report on Form 10-Q for the fiscal quarter ended September 30, 2008, and Current Reports on Form 8-K filed from time to time by the Company.

SOURCE: Clinical Data, Inc.

Clinical Data, Inc.

Theresa McNeely, 617-527-9933 x 3373

Vice President

Corporate Communications

or

General Business Inquiries

617-527-9933 x 3388

Copyright Business Wire 2008

News Provided by COMTEX